Comparison of efficacy of conjugated estrogen cream 0.625% plus clobetasol 0.05% vs. clobetasol 0.05% alone in the treatment of vitiligo patients
Keywords:
Vitiligo, melanocyte, treatment, clobetasol, estrogenAbstract
Background: Vitiligo is a pigmentary skin disorder characterized by hypo- or depigmented patches. Topical steroid creams are used as a common standard method in vitiligo therapy. Objective The goal of this study was to compare the efficacy of topical clobetasol (as a standard method for treatment of vitiligo) versus combination of clobetasol + topical estrogen in treatment of vitiligo. Patients and methods In this double-blind clinical trial, 37 patients who had at least 2 vitiligo patches were treated with topical clobetasol on one side of the body for three months while a combination of clobetasol and estrogen was applied on the other side. Three months after termination of therapy, the patients were visited again for improvement of disease. The results were evaluated with statistical analysis of paired t test, McNemar and Wilcoxon tests in SPSS software. Results Overall 37 patients, 21 women and 16 men with minimum age of 14 and maximum of 45 years old, completed the study. The difference of average area of lesions before and after treatment in clobetasol and estrogen group was significantly more than clobetasol only group (P=0.001). There was no significant difference between clobetasol and clobetasol + estrogen treatment for two age groups of 14-30 and 31-45 years. Also the pigmentation score of two treatment groups measured by paired sample test was not significant for both sexes (P> 0.05). Conclusion Addition of estrogen to clobetasol increases its efficiency in treatment of vitiligo without any side effects. Also it seems that estrogen may decrease the topical clobetasol complications such as atrophy, erythema and telangiectasia.ÂReferences
Koranue RV , Sachdeva KG. Vitiligo. Int J Dermatol 1988; 27: 676-81.
Lerner AB. On the etiology of vitiligo and gray hair. Am J Med 1971; 51: 141-7.
Ortonne J-P, Mosher DB, Fitzpatrick TB, eds. In: Vitiligo and other Hypomelanoses of Hair and Skin. New York: Plenum medical; 1983. P. 129-310.
Handa H, Dogra S. Epidemiology of childhood vitiligo: Ped Dermatol 2003; 20: 107-10.
Oh H S, Smart R C. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. Proc Nat Acad Sci USA 1996; 93: 12525-30.
Mohr J. Vitiligo in a pair of monozygotic twins. Acta Genet 1951; 2: 252-5.
Cui J. Artia Y, Bystryn J-C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100: 812-15.
Betterle C, Peserico A, Bersani G. Vitiligo and autoimmune polyendocrine deficiencies with autoantibodies to melanin – producing cells. Arch Dermatol 1979; 115: 364.
Woolfson H, Finn OA, Mackie RM et al. Serum anti – tumour antibodies and auto-antibodies in vitiligo. Br J Dermatol 1975; 92: 395-400.
Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. Pigment Cell Res 2007, 20: 271-8.
Jin Y, Mailloux CM, Gowan K et al. NALP1 in vitiligo-associated multiple autoimmune disease. New Eng J Med 2007; 356: 1216-25.
Kemp FH, Waterman EA, Hawes BE et al. The melanocortin receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002; 109: 923-30.
Lerner AB. Vitiligo. J Invest Dermatol 1959; 32: 285.
Dell' Anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19: 406-11.
Calvin M. Oestrogens and wound healing. Maturitas 2000; 34: 195-210.
Dolatshahi M, Ghazi P, Feizi V, Hemami M R. Life quality assessment among patients with vitiligo. Indian J Dermatol Venereol Leprol 2008; 74: 700.
Papadopoulos L. Psychological therapies for dermatological problems. In Walker C, Papadopoulos L, eds. Psychodermatology: The psychological impact of skin disorders. Cambridge, UK: Cambridge University; 2005. P. 101-115.
Ashcroft GS, Ashworth JJ. Potential role of estrogen in wound healing. Am J Clin Dermatol 2003: 4 : 737-43.
Varila E, Rantala I, Orikarinen A et al. The effect of topical estradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995: 120: 985-9.
Sauerbonn AVD, Fonseca AM, Bagnoli VR et al. The effect of systemic hormone replacement therapy on the skin of the postmenopausal women. Int J Gynecol Obstet 2000: 68: 35-41.
Risteli J. Effect of prednisolone on the activities of intercellular enzymes of collagen biosynthesis in rat skin. Biochem Pharmacol 1977: 26: 1295-8.
Autio P, Oikarinen A, Melkko J et al. Systemic glucocorticoids decrease the synthesis of type I and III collagen in human skin in vivo, whereas isotretinoin has little effect. Br J Dermatol 1994; 131: 660-3.
Nuutinen P, Riekki R, Parikka M et al. Modulation of collagen synthesis and MRNA by continuous and intermittent use of topical hydrocortisone in human skin. Br J Dermatol 2003; 148: 39-45.
Verdier-Sevrain S, Bonte F, Gilchrest B. Biology of estrogens in skin. Exp Dermatol 2006: 15: 83-94.
Thornton M.J. I. The biological actions of estrogens on skin. Exp Dermatol 2000: 11 : 487-502.
Grimes PE, New insights and new therapies in vitiligo. JAMA 2005; 293: 730-5.
Njoo MD, Spuls PI, Bosy D et al. Non surgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998; 134: 1532-40.
Philips TJ, Dermicary Z, Sahu M. Hormonal effects on skin aging. Clin Geriatr Med 2001: 17: 661-672
Snell R.S, Turner R. Skin pigmentation in relation to the menstrual cycle. J Invest Dermatol 1966: 47: 147-5.
Beas F. Vargas L, Spada RP, Merchak N. Pseudoprecocious puberty in infants caused by a dermal ointment containing estrogen. J Pediatr 1969: 75: 125-30.
Im S, Lee ES, Kim W et al. Donor specific response of estrogen and progesterone on cultured human melanocytes. J Korean Med Sci 2002; 17: 58-64.
Ranson M, Posen S, Mason RS. Human melanocytes as a target tissue for hormones. in vitro studies with 1 alpha-25, dihydroxy vitamin D3, alpha-melanocyte stimulating hormone and beta-estradiol. J Invest Dermatol 1988: 91:593-8.
Kippenberger S, Lotisch S, Solano F et al. Quantification of tyrosinase, TRP-1 and TRP-2 transcripts in human melanocytes by reverse transcriptase- competitive multiplex PCR regulation by estroid hormones. J Invest Dermatol 1998: 110: 364-7.
Nussey SS, Wwitehead SA, eds. Endocrinology: An integrated approach, 1st edn. Oxford: BIOS Scientific Publishers; 2001.
